Alphatec (NASDAQ:ATEC) Stock Gets Price Target Cut from JPMorgan Chase & Co.

Alphatec (NASDAQ:ATEC) had its target price lowered by JPMorgan Chase & Co. from $16.00 to $15.00 in a research note issued to investors on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the medical technology company’s stock.

A number of other research firms also recently weighed in on ATEC. Stifel Nicolaus dropped their target price on Alphatec from $16.00 to $13.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. BMO Capital Markets downgraded Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 price objective for the company. in a report on Friday. Stephens assumed coverage on Alphatec in a report on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price target for the company. Wells Fargo & Company dropped their price objective on shares of Alphatec from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday. Finally, UBS Group lifted their price objective on shares of Alphatec from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Alphatec currently has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Alphatec Price Performance

ATEC opened at $7.04 on Friday. Alphatec has a 52 week low of $6.81 and a 52 week high of $23.29. The firm has a 50-day simple moving average of $10.14 and a two-hundred day simple moving average of $10.62. The company has a market capitalization of $1.09 billion, a PE ratio of -12.80 and a beta of 0.88.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The business had revenue of $221.17 million for the quarter, compared to analysts’ expectations of $225.16 million. During the same quarter last year, the company earned $0.03 earnings per share. The firm’s revenue for the quarter was up 12.6% on a year-over-year basis. As a group, sell-side analysts expect that Alphatec will post -0.45 earnings per share for the current year.

Insider Activity at Alphatec

In other Alphatec news, General Counsel Tyson Marshall sold 8,168 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $9.65, for a total value of $78,821.20. Following the sale, the general counsel owned 630,398 shares in the company, valued at $6,083,340.70. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles bought 115,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were acquired at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the transaction, the chief executive officer directly owned 5,893,551 shares of the company’s stock, valued at $51,922,184.31. This trade represents a 1.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 13.48% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Large investors have recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC bought a new position in shares of Alphatec in the third quarter valued at $112,000. State of Wyoming increased its holdings in Alphatec by 87.7% during the 3rd quarter. State of Wyoming now owns 30,666 shares of the medical technology company’s stock worth $316,000 after purchasing an additional 14,328 shares in the last quarter. Sterling Capital Management LLC raised its holdings in shares of Alphatec by 841.5% in the 3rd quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company’s stock valued at $42,000 after purchasing an additional 3,669 shares during the period. Kopp Family Office LLC boosted its stake in shares of Alphatec by 0.4% in the third quarter. Kopp Family Office LLC now owns 330,266 shares of the medical technology company’s stock valued at $3,408,000 after buying an additional 1,303 shares during the period. Finally, AA Financial Advisors LLC increased its position in Alphatec by 140.5% during the 3rd quarter. AA Financial Advisors LLC now owns 48,094 shares of the medical technology company’s stock worth $496,000 after purchasing an additional 28,094 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors.

Key Headlines Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue increased 12.6% year over year to approximately $221.2 million, while earnings of $0.09 per share improved from $0.03 a year earlier. Management continues to target a 16% adjusted EBITDA margin for 2026. Alphatec third-quarter results
• Positive Sentiment: Wells Fargo lowered its price target from $14 to $12 but maintained an “overweight” rating, implying substantial potential upside if Alphatec stabilizes growth and executes on its profitability plans. Wells Fargo rating
• Neutral Sentiment: Analyst expectations remain divided: BMO Capital Markets downgraded the stock to “market perform” with an $8 price target, while other analysts continue to see valuation upside. BMO Capital Markets rating
• Negative Sentiment: Alphatec reduced its 2026 revenue outlook to approximately $862 million from roughly $882 million, below the prior market expectation. Management cited fewer surgeons purchasing its bone-graft products used in spinal-fusion procedures. Alphatec guidance reduction
• Negative Sentiment: Third-quarter adjusted earnings of $0.09 per share and revenue of $221.2 million both missed analyst estimates, reinforcing concerns about slowing demand despite year-over-year growth. Alphatec earnings miss
• Negative Sentiment: Levi & Korsinsky and Ademi LLP announced investigations into potential securities-law violations related to Alphatec’s outlook and subsequent decline. These notices may add reputational and legal risk, although they do not establish wrongdoing. Alphatec investor investigation

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.